Bicycle Therapeutics (BCYC) Revenue & Revenue Breakdown
Bicycle Therapeutics Revenue Highlights
Latest Revenue (Y)
$26.98M
Latest Revenue (Q)
$2.68M
Bicycle Therapeutics Revenue by Period
Bicycle Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $26.98M | 86.52% |
2022-12-31 | $14.46M | 23.65% |
2021-12-31 | $11.70M | 12.58% |
2020-12-31 | $10.39M | -24.72% |
2019-12-31 | $13.80M | 93.40% |
2018-12-31 | $7.14M | 246.41% |
2017-12-31 | $2.06M | - |
Bicycle Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $2.68M | -71.45% |
2024-06-30 | $9.37M | -51.99% |
2024-03-31 | $19.52M | 266.14% |
2023-12-31 | $5.33M | -0.39% |
2023-09-30 | $5.35M | -53.04% |
2023-06-30 | $11.40M | 132.78% |
2023-03-31 | $4.90M | 53.72% |
2022-12-31 | $3.19M | 4.77% |
2022-09-30 | $3.04M | -30.56% |
2022-06-30 | $4.38M | 13.42% |
2022-03-31 | $3.86M | 2.36% |
2021-12-31 | $3.77M | -12.97% |
2021-09-30 | $4.33M | 142.75% |
2021-06-30 | $1.78M | -1.27% |
2021-03-31 | $1.81M | -53.01% |
2020-12-31 | $3.85M | 0.16% |
2020-09-30 | $3.84M | 144.56% |
2020-06-30 | $1.57M | 39.15% |
2020-03-31 | $1.13M | -78.62% |
2019-12-31 | $5.28M | 760.10% |
2019-09-30 | $614.00K | -59.66% |
2019-06-30 | $1.52M | -76.16% |
2019-03-31 | $6.38M | 503.97% |
2018-12-31 | $1.06M | -34.35% |
2018-09-30 | $1.61M | -3.07% |
2018-06-30 | $1.66M | -40.85% |
2018-03-31 | $2.81M | 328.70% |
2017-12-31 | $655.00K | - |
Bicycle Therapeutics Revenue Breakdown
Bicycle Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Sep 21 | Mar 21 |
---|---|---|
Target 6 Material Right | $1.10M | - |
Target Four Material Right | - | $300.00K |
Latest
Bicycle Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Sep 21 | Mar 21 |
---|---|---|
Target 6 Material Right | $1.10M | - |
Target Four Material Right | - | $300.00K |
Latest
Bicycle Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
MRUS | Merus | $43.95M | $11.77M |
BCYC | Bicycle Therapeutics | $26.98M | $2.68M |
IDYA | IDEAYA Biosciences | $23.39M | - |
ADAG | Adagene | $18.11M | $833.34K |
ANAB | AnaptysBio | $17.16M | $30.02M |
SEER | Seer | $16.66M | $4.03M |
MGTX | MeiraGTx | $14.02M | $10.91M |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
IGMS | IGM Biosciences | $2.13M | $516.00K |
INBX | Inhibrx Biosciences | $1.80M | - |
FIXX | Q32 Bio | $1.16M | - |
KROS | Keros Therapeutics | $151.00K | $37.00K |
ANEB | Anebulo Pharmaceuticals | - | - |
CGEM | Cullinan Oncology | - | - |
CCCC | C4 Therapeutics | - | - |
ACRV | Acrivon Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
ORIC | ORIC Pharmaceuticals | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |
TNYA | Tenaya Therapeutics | - | - |